Lexgenleucel-T - VIRxSYS Corporation
Alternative Names: Anti-HIV gene therapy - VIRxSYS; VRX 496; VRX496Latest Information Update: 02 Oct 2021
At a glance
- Originator VIRxSYS Corporation
- Developer University of Pennsylvania; VIRxSYS Corporation
- Class Antivirals; Gene therapies; T lymphocyte cell therapies
- Mechanism of Action HIV replication inhibitors; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II HIV infections